ABSTRACT Commercial preparations of conjugated linoleic acid (CLA) contain both positional and geometric isomers of octadecadienoic acid, with cis-9,trans-11 CLA (c9t11) and trans-10,cis-12 CLA (t10c12) as the principal isomers. We showed previously that CLA reduced the incidence of colon tumors in rats treated with 1,2-dimethylhydrazine. In addition, our previous in vitro studies showed that t10c12 inhibited the growth of HT-29 and Caco-2 human colon cancer cells, whereas c9t11 had no effect on cell growth. In the present study, to examine the effects of the CLA isomers on cell cycle and cell cycle regulatory proteins, we treated HT-29 cells with various concentrations (0-4 mmol/L) of the individual CLA isomers. A DNA flow cytometric analysis revealed that t10c12 induced a G 1 arrest, whereas c9t11 had no effect on the cell cycle. Western blot analysis of total cell lysates revealed no alteration in the protein expression of cyclin A, cyclin D, cyclin E, cyclin-dependent kinase (CDK) 2, or CDK4 due to t10c12 treatment. However, t10c12 substantially increased the protein expression and mRNA accumulation of the CDK inhibitor p21 CIP1/WAF1 . The t10c12 isomer increased the association of p21 CIP1/WAF1 with CDK2 and proliferating cell nuclear antigen, but decreased the levels of phosphorylated retinoblastoma protein (Rb), with an increase in the levels of hypophosphorylated Rb protein. An in vitro kinase assay using histone H1 as a substrate showed that the activities of CDK2 were significantly decreased by t10c12. These results indicate that t10c12 exerts its growth inhibitory effects in colon cancer cells through the induction of G 1 cell cycle arrest. The induction of p21 CIP1/WAF1 may be one of the mechanisms by which t10c12 inhibits cell cycle progression in HT-29 cells. J. Nutr. 136: 893-898, 2006. KEY WORDS: conjugated linoleic acid cell cycle cyclin-dependent kinase retinoblastoma protein p21 CIP1/WAF1
Colon cancer, next to lung cancer for men and breast cancer for women, is the second-most frequent cancer in Europe and North America (1), with the incidence of this disease also rapidly increasing in Oriental countries. Despite substantial information on the mechanisms of carcinogenesis, the survival of patients with advanced solid tumors has not increased considerably over the past 30 y (2). Recently, dietary compounds that have potential for cancer treatment have been under intensive investigation.
Conjugated linoleic acid (CLA) 3 denotes a series of positional and geometric isomers of octadecadienoic acid; 2 of these [cis-9,trans-11 CLA (c9t11) and trans-10,cis-12 CLA (t10c12)] are reported to possess biological activity (3) . CLA was shown to elicit cancer protection in a variety of experimental carcinogenesis models, including that of colon cancer. Much of this research involved feeding animals mixtures of CLA isomers, containing predominantly c9t11 and t10c12 in approximately equal amounts, with other CLA isomers at much lower levels [reviewed in (4) ]. Evidence exists that the various biological effects of CLA are attributable to the separate actions of the c9t11 and t10c12 isomers (3), even though some effects are likely to be induced and/or enhanced synergistically by these isomers. However, the molecular mechanisms of the antitumor activity of CLA isomers remain to be elucidated.
One of the most common events required for human cancer development is deregulation of the cell cycle mechanism (5,6). The mammalian cell cycle is divided into 4 separate phases, referred to as the G 1 , S, G 2 , and M phases. During the G 1 phase, cells respond to extracellular signals by either advancing toward another division or withdrawing from the cycle into a resting state (G 0 ) (7) (8) (9) . The mammalian cell cycle progression is controlled by the sequential activation and inactivation of several cyclin-dependent kinases (CDK) (10) . CDK 2 and 4/6, in association with cyclins D, E, and A, sequentially phosphorylate the retinoblastoma protein (Rb), and regulate the G 1 !S phase transition and progression through the S phase (11) . Cyclin-dependent kinase inhibitors (CKI), which bind and inhibit the activity of CDK, play crucial roles in inhibiting cell proliferation. p21 CIP1/WAF1 is the founding member of the CIP/ KIP family of CKI, which also includes p27 KIP1 and p57 KIP2 (12, 13) . In addition to its ability to inhibit CDK, p21
can also bind and inhibit the activity of proliferating cell nuclear antigen (PCNA) (14, 15) . Because autonomous cell proliferation is a characteristic of cancer cells, cell cycle regulatory proteins are promising targets for cancer therapy. We reported previously that dietary CLA reduces tumor incidence in the colon of 1,2-dimethylhydrazine-treated rats (16) . In addition, our in vitro study showed that CLA inhibits the G 1 !S cell cycle progression in HT-29 cells by inducing p21 CIP1/WAF1 (17) . We also observed that t10c12 inhibits the growth of HT-29 and Caco-2 human colon cancer cells, whereas c9t11 had no effect on the growth (18,19). The present study examined the effect of CLA isomers on the cell cycle progression of HT-29 cells.
MATERIALS AND METHODS
Materials. We purchased reagents from the following suppliers: c9t11 and t10c12 (Cayman Chemical); anti-b-actin, essentially fatty acid-free bovine serum albumin (BSA), ascorbic acid, a-tocopherol phosphate, and transferrin (Sigma Chemical); selenium and DMEM/ Ham's F-12 nutrient mixture (DMEM/F-12; Gibco BRL); horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse IgG (Amersham); [g- Cell culture. The HT-29 cell line was obtained from the American Type Culture Collection and maintained in DMEM/F12, containing 100 mL/L fetal bovine serum (FBS) with 100,000 U/L penicillin and 100 mg/L streptomycin. We used HT-29 cells between passages 137 and 148 in these studies. To examine the effect of the CLA isomers, we plated the cells with DMEM/F-12 containing 10% FBS. Before the CLA treatment, we rinsed the cell monolayers and serum-starved them for 24 h, with DMEM/F-12 supplemented with 5 mg/L transferrin, 1 g/L BSA, 5 mg/L selenium, 50 mg/L ascorbic acid, and 20 mg/L a-tocopherol phosphate (serum-free medium). After serum-starvation, we replenished the monolayers with fresh serum-free medium, with or without the indicated concentrations of the individual CLA isomers. We made the CLA isomer complexes with essentially fatty acid-free BSA, with a molar ratio of CLA isomer to BSA of 4:1 (20) . The medium was changed every 2 d.
Flow cytometric analysis of cell cycle distribution. We plated the cells in 24-well plate, at 50,000 cells/well, in DMEM/F12 containing 10% FBS. We serum starved and then treated the cells with the indicated concentrations of the CLA isomers, as described above. Cells were separated by trypsin-EDTA, treated with RNase, and the cellular DNA was then stained with propidium iodide, as previously described (17) . The percentages of cells in the G 1 , S, and G 2 /M phases of the cell cycle were analyzed by flow cytometry. The proportion of nuclei in each phase of the cell cycle was determined using the Modfit version 1.2 software (Becton Dickinson). [ 3 H]Thymidine incorporation into the DNA of HT-29 cells was determined, as described earlier (19). The viable cell number was determined in duplicate wells, using the MTT assay, as described previously (21) Immunoprecipitation and Western blot analyses. The cells were lysed in ice-cold lysis buffer, as previously described (22) , and the protein content was determined using the bicinchoninic acid protein assay kit (Pierce). Cell lysates (0.75 mg protein) were precleaned with 1 mg of normal rabbit IgG and 50 mL of protein A-Sepharose bead slurry (Amersham) by incubation on an end-over-end mixer for 1 h at 48C, and then centrifugation at 14,000 3 g for 10 min at 48C. The precleaned lysates were incubated with 5 mg of an anti-CDK2 or anti-PCNA antibody for 1 h at 48C. Protein A-Sepharose was added, and the mixture was incubated for a further 1 h at 48C; the beads then washed 4 times with lysis buffer by centrifuging at 600 3 g for 5 min at 48C. Total cell lysates (50 mg protein) or immunoprecipitated proteins were resolved on a SDS-PAGE (4-20% or 10-20%) and transferred onto a polyvinylidene fluoride membrane (Millipore). The blots were blocked for 1 h with 5% skimmed milk dissolved in 20 mmol/L TrisHCl, pH 7.5, 150 mmol/L NaCl, 0.1% Tween 20, and then incubated for 1 h with anti-p21 CIP1/WAF1 (1:1000), p27 KIP1 (1:1000), anti-cyclin D1 (1:200), anti-cyclin A (1:1000), anti-cyclin E (1:1000), anti-CDK2 (1:1000), anti-CDK4 (1:1000), anti-phospho-Rb (1:1000), anti-Rb (1:1000), anti-PCNA (1:1000), or anti-b-actin (1:2000) antibody. The blots were then incubated with anti-mouse or rabbit HRPconjugated antibody. Signals were detected based on an enhanced chemiluminescence method using the SuperSignalÒ West Dura Extended Duration Substrate (Pierce). Densitometric analysis was carried out using the Bio-profile Bio-ID application (Vilber-Lourmat). Expression levels were normalized to b-actin, with the control (0 mmol/L CLA isomer) level set at 100%.
Reverse transcription-PCR. Total RNA was isolated using Tri reagent (Sigma) and cDNA synthesized using 2 mg of total RNA and SuperScriptä II reverse transcriptase (Invitrogen), as described previously (22) . Amplication of cDNA was performed, as previously described (17) . For each combination of primers, the kinetics of the PCR amplication were studied, the number of cycles corresponding to the plateau determined, and PCR performed within an exponential range. PCR products were separated on a 2% agarose gel and stained with ethidium bromide. Bands corresponding to each specific PCR product were quantified by densitometric scanning of the exposed film using the Bio-profile Bio-ID application (Vilber-Lourmat). The mRNA levels were normalized to b-actin, with the control (0 mmol/L CLA isomer) level set at 100%.
CDK2 activity: in vitro kinase assay. Cell lysates (0.75 mg protein) were immunoprecipitated with polyclonal antibody against CDK2 and protein A-Sepharose, and the immune complex washed with 20 mmol/L Tris-HCl, pH 7.5, and 4 mmol/L MgCl 2 (kinase buffer). After being washed, the beads were incubated with 15 mL of kinase buffer, with 2 mg of histone H1 (Roche) and 3 mCi of [g-32 P]ATP, at 378C for 30 min. The reaction was stopped by boiling the samples in SDS sample buffer for 5 min. The 32 P-labeled histone H1 was resolved on a SDS-PAGE, and the gel dried and subjected to autoradiography. Signals were quantified by densitometric scanning of the exposed film.
Statistical analysis. The results are expressed as means 6 SEM, and were further analyzed by ANOVA. Differences among treatment groups were analyzed using Duncan's multiple range test, utilizing the SAS system for Windows V8.12 (SAS Institute). Differences were considered significant at P , 0.05.
RESULTS

T10c12
, not c9t11, induces G 1 arrest. We first determined which of the CLA isomers (t10c12 or c9t11) regulates the cell cycle progression of HT-29 cells. In the presence of t10c12, we observed a dose-dependent increase in the percentage of cells in the G 1 phase; this accumulation was accompanied by a corresponding reduction in the percentages of cells in the S and G 2 /M phases ( Table 1) . However, c9t11
did not affect the cell cycle transition (data not shown). (Table 1) , whereas c9t11 had no effect on DNA synthesis (data not shown). T10c12, not c9t11, increases p21 CIP1/WAF1 levels. Western blot analysis of total cell lysates revealed that neither c9t11 nor t10c12 had an effect on the protein levels of either CDK2 or CDK4 (data not shown). The levels of cyclins A, D1, and E remained unaltered in HT-29 cells upon treatment with the CLA isomers (data not shown). T10c12 markedly increased the expression of p21 CIP1/WAF1 , in a dose-dependent manner, with a 1400% increase in p21 CIP1/WAF1 protein levels after the addition of 4 mmol/L t10c12 (Fig. 1A) , whereas c9t11 had no effect (Fig. 1B) . Neither c9t11 nor t10c12 altered the protein expression of p27 KIP1 (Fig. 1A and B) . To determine whether t10c12 regulates the expression of p21 CIP1/WAF1 at the RNA level, we performed RT-PCR analyses. Treatment of HT-29 cells with increasing concentrations of t10c12 increased p21 CIP1/WAF1 mRNA levels in a concentration-dependent manner, with a 950% increase in p21 CIP1/WAF1 transcripts after the addition of 4 mmol/L t10c12 (Fig. 1C) .
T10c12 decreases CDK2 activity. The activity of CDK2 decreased in a dose-dependent manner after t10c12 treatment. The decrease in CDK2 activity occurred in concert with enhanced binding of p21 CIP1/WAF1 (Fig. 2) . Therefore, p21
CIP1/WAF1 , which was increased after the treatment of HT-29 cells with t10c12, binds to CDK2 and inhibits its activity.
T10c12, not c9t11, decreases hyperphosphorylated Rb but increases hypophosphorylated Rb. Western blot analysis of total cell lysates with phospho-Rb antibody revealed a decrease in the phosphorylated Rb levels, in a t10c12 dose-dependent manner (Fig. 3) . When the immunoblot was probed using the total Rb antibody, 2 bands were detected; hyperphosphorylated and hypophosphorylated Rb. A t10c12 dose-dependent decrease in the intensity of the upper band (hyperphosphorylated Rb) was detected, whereas the intensity of the lower band (hypophosphorylated Rb) was increased in cells treated with 4 mmol/L t10c12. However, c9t11 did not affect either the hyperphosphorylated or hypophosphorylated Rb levels (Fig. 3) .
T10c12 increases the levels of p21 CIP1/WAF1 associated with PCNA. Western blot analysis of total cell lysates showed that t10c12 did not change the expression of PCNA protein (Fig. 4) . To determine whether t10c12 increases the levels of p21 CIP1/WAF1 associated with PCNA, immunoprecipitation was performed with the anti-PCNA antibody, followed by immunoblotting with the anti-p21 CIP1/WAF1 antibody. Consistent with the results from Western blot analysis, the immunoprecipitated PCNA was not affected by t10c12 treatment. However, the levels of p21 CIP1/WAF1 associated with PCNA were significantly increased, in a concentration-dependent manner.
DISCUSSION
A deregulation of the cell cycle checkpoints is a common abnormality observed in human cancers. Most human cancers experience CDK hyperactivation, which leads to the inactivation of the Rb pathway. Accordingly, new CDK inhibitors are being developed for cancer therapy (23) . CLA is currently under intensive investigation due to its health-promoting potential; in this study, we emphasize the cancer treatment potential of one isomer of CLA. A number of investigators showed that CLA inhibits carcinogenesis in experimental animals and modulates cell proliferation and apoptosis (24). The present study was performed to determine whether the 2 main CLA isomers in commercial preparations have any effect on cell cycle progression in HT-29 colon cancer cells. We observed that t10c12 induced G 1 arrest at a concentration as low as 2 mmol/L, whereas c9t11 had no effect, which is in accordance with our observations that t10c12 inhibited the growth of colon cancer cells, whereas c9t11 did not (19, 25) . In addition, t10c12 was shown to reduce insulin-like growth factor-II secretion (19, 26) and ErbB3 signaling in HT-29 cells (18), whereas c9t11 had no effect.
Normal concentrations of CLA in human sera were reported to be in the 7-70 mmol/L range, whereas levels . 100 mmol/L were detected in chronic alcoholics and patients with liver disease (27) (28) (29) . Concentrations up to 5 times that found in normal serum were reached in humans after supplementation with 2.1 g CLA for 45 d (30) . The main food source of CLA in the Western diet is meat and dairy products derived from ruminant animals with ratios of c9t11 to t10c12 of 30-70:1. However, in most of animal and human studies, commercial preparations of CLA are used as a 1:1 mixture of the 2 isomers [reviewed in (31)]. Therefore, the concentrations of the CLA isomers used in the present study are physiologically achievable if CLA-rich natural products and commercially prepared CLA are consumed.
In the present study, we showed that t10c12 treatment leads to increased expression of the CDK inhibitor p21 CIP1/WAF1 . Transcription of the p21 gene is regulated by both p53-dependent and independent mechanisms (32) . In HT-29 cells, t10c12 induces p21 mRNA levels in a p53-independent manner because these cells lack functional p53 (33) . Induction of p21 CIP1/WAF1 can lead to G 1 arrest by inhibition of the cyclin D-, E-, and A-dependent kinases (34,35). Overexpression of p21 CIP1/WAF1 is reported to inhibit the proliferation of mammalian cells (35, 36) . Our data indicate that physiological levels of t10c12 are capable of inducing sufficient levels of p21 CIP1/WAF1 to inhibit both CDK activity and progression from the G 1 !S phase. Additional work is warranted to identify the nature of the molecules required for t10c12 to induce p21 CIP1/WAF1 gene expression. CDK phosphorylate members of the Rb protein family, with the progression from the G 1 !S phase coinciding with the phosphorylation and consequent inactivation of Rb proteins [reviewed in (37) ]. Cyclin D-dependent kinases initiate Rb phosphorylation at or near the restriction check-point of G 0 -G 1 , after which cyclin E-CDK2 becomes active, completing this process by phosphorylating Rb on additional sites (7, 38, 39) . In quiescent cells, hypophosphorylated Rb associates with a family of transcriptional regulators, the E2F proteins (7, 40, 41) . Phosphorylation of Rb proteins impairs binding to the E2F ) or an in vitro kinase assay using histone H1 as a substrate. Photographs of chemiluminescent detection of the blots (CDK2 and p21 CIP1/WAF1 protein) or an autoradiograph of the dried gel (CDK2 activity) are shown; these are representative of 3 independent experiments. The relative abundance of each band to its own CDK2 was quantified, with the control level set at 100%. The adjusted mean 6 SEM (n ¼ 3) of each band is shown above each blot. Means without a common letter differ, P , 0.05. . Photographs of chemiluminescent detection of the blots are shown; these are representative of 3 independent experiments. The relative fold change in p21 CIP1/WAF1 to its own PCNA protein band was quantified by densitometry, with the control (0 mmol/L t10c12) level set at 100%. The adjusted mean 6 SEM (n ¼ 3) of each band is shown above each blot. Means without a common letter differ, P , 0.05.
proteins, which allows them to act as transcription activators. E2F target genes that are upregulated as a result of Rb phosphorylation include those necessary for the completion of the G 1 !S phase transition, as well as for DNA replication (42) . In the present study, t10c12 dose dependently decreased the phospho-Rb levels, indicating that induction of p21 CIP1/WAF1 by t10c12 leads to inhibition of CDK activity, which results in decreased phosphorylation of CDK substrates. Utilizing MCF-7 breast cancer cells, Kemp et al. (43) showed that t10c12 (10 mmol/L) increased the accumulation of Rb. These results indicate that the decreased phospho-Rb (the increased hypophosphorylated Rb) contributes to the G 0 /G 1 arrest observed in t10c12-treated cells.
The present data indicate that increased p21 CIP1/WAF1 plays a role in t10c12-induced G 1 arrest by binding and inhibiting the activity of CDK2. In addition to its interactions with cyclin-CDK complexes, p21 CIP1/WAF1 may also inhibit cell cycle progression via the interaction with PCNA (44,45). PCNA, a processivity factor for DNA polymerase d, is one of the central molecules responsible for the decisions concerning the life and death of the cell (46) . The C terminus of p21 CIP1/WAF1 , containing its nuclear localization signal, binds to and inhibits PCNA, thereby blocking DNA replication (12) . The present study demonstrated that t10c12 upregulates the level of p21 CIP1/WAF1 and its interaction with PCNA, which may also contribute to the observed decreased DNA synthesis.
We observed previously that in addition to inducing growth arrest, t10c12 treatment also induced apoptosis of Caco-2 human colon carcinoma cells (19, 47) . Although the expression of p21 CIP1/WAF1 often acts as an inhibitor of apoptosis [reviewed in (32) ], it was also shown to increase apoptosis in some systems (48-53). Several groups also reported that disruption of p21 CIP1/WAF1 expression leads to decreased cell death, suggesting that this CDK inhibitor has proapoptotic roles under some conditions (54-57). Poole et al. (57) showed decreased apoptosis of colonic epithelial cells in mice deficient of p21 CIP1/WAF1 after treatment with the colon carcinogen, azoyxymethane. It is likely that the induction of p21 CIP1/WAF1 contributes to both growth arrest and apoptosis in t10c12-teated colon cancer cells. Apoptosis provides a principal protective mechanism for disposing of damaged cells that may escape growth control and would contribute to the potential therapeutic benefits of t10c12.
In conclusion, the present study showed that t10c12 induced cell cycle arrest at the G 0 /G 1 phase. An increase in the levels of p21 CIP1/WAF1 in t10c12-treated cells led to the inhibition of the CDK activity, which resulted in a decrease in phosphorylated Rb and an increase in hypophosphorylated Rb. In addition, the increased p21 CIP1/WAF1 bound to PCNA may have blocked the ability of PCNA to activate DNA polymerase. Together, these effects caused an arrest in the G 1 !S cell cycle progression, followed by inhibition of HT-29 cell proliferation. Because CDK inhibitors are thought to hold considerable potential for the inhibitory control of cancer cell proliferation, these results suggest that increasing the t10c12 level of certain foods, and combining t10c12 intake with traditional chemotherapy, could be good approaches for treating colon cancer.
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